Clinical trials: Acute Ischemic Stroke Patients
Ischemic Stroke
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care.
- Trial name
- SP-8203-2002 (NCT04479449)
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Acute Ischemic Stroke AIS
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
- Trial name
- STEVIA (NCT06995625)
- Testing
- SNE-101
- Where
- 3 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- S&Ebio Co. Ltd.
Ischemic Stroke
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke.
- Trial name
- CASTA (NCT00868283)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 49 sites in China, Hong Kong and 1 more
- Volunteers
- 1,071 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Ischemic Stroke
Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy
Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke
- Trial name
- iNFLOW-5 (NCT07571954)
- Testing
- Thromboaspiration catheter
- Where
- 7 sites in France, Spain
- Volunteers
- 45 people
- Sponsor
- iVascular S.L.U.
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Acute Ischaemic Stroke
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
This is a randomized, rt-PA controlled, open-label phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus rt-PA thrombolysis for patients with acute ischaemic stroke in 4.5…
- Trial name
- NCT03541668
- Testing
- Recombinant human urokinase, Alteplase
- Where
- 35 sites in China
- Volunteers
- 674 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Acute Ischemic Stroke
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
The goal of this clinical trial is to learn if AB126, an investigational treatment made from neural exosomes, is safe and well tolerated when given to adults with moderate to severe acute ischemic stroke (AIS) who have undergone…
- Trial name
- NEXIS (NCT07813130)
- Testing
- AB126 Neural Exosomes Intravenous Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aruna Bio, Inc.
Acute Ischemic Stroke, rhTNK-tPA
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse®) as the control.
- Trial name
- NCT07519889
- Testing
- rhTNK-tPA, rt-PA
- Volunteers
- 4,500 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Acute Ischemic Stroke
SUMMIT RISE Study of Acute Ischemic Stroke Patients
SUMMIT RISE Study of Acute Ischemic Stroke Patients
- Trial name
- NCT07436156
- Testing
- Route 92 Medical Reperfusion Systems
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Route 92 Medical, Inc.
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Acute Ischemic Stroke
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).
- Trial name
- NCT07739160
- Testing
- HRS-4029
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Ischemic Stroke
ReStore Thrombectomy Trial for Flow Restoration in Acute Ischemic Stroke Patients
The ReStore™ Thrombectomy device restores blood flow in the neurovascular by removing thrombus in patients experiencing ischemic stroke.
- Trial name
- NCT01437774
- Testing
- thrombectomy (ReStore or Merci)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Reverse Medical Corporation
Stroke
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more…
- Trial name
- GMAIS (NCT01221246)
- Testing
- GM602
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Acute Stroke, Cerebral Ischemia
PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in…
- Trial name
- NCT04046484
- Testing
- Normal Saline along with standard treatment, PMZ-1620 along with standard treatment
- Where
- 7 sites in India
- Volunteers
- 40 people
- Sponsor
- Pharmazz, Inc.
Acute Ischemic Stroke
A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)
The objective of this study is to evaluate the safety and efficacy of a single intravenous administration of JTR-161 (allogeneic stem cell product derived from the dental pulp of healthy adult humans) to patients with acute…
- Trial name
- J-REPAIR (NCT04608838)
- Testing
- JTR-161
- Where
- Japan
- Volunteers
- 79 people
- Sponsor
- Teijin Pharma Limited
Stroke
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.
- Trial name
- NCT02251197
- Testing
- BIII 890 CL
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke AIS
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
The study will evaluate the efficacy and safety of SIM0811 in participants with acute ischemic stroke who are present within 4.5 to 24 hours since last known well. The main questions it aims to answer are: 1.
- Trial name
- NCT07903701
- Testing
- SIM0811 Dose Level A (Phase II), SIM0811 Dose Level B (Phase II), SIM0811 Dose Level C (Phase II)
- Volunteers
- 1,092 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Ischemic Stroke
A Study of NCS-01 in Patients With Acute Ischemic Stroke
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset.
- Trial name
- NCT03915431
- Testing
- NCS-01
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NC Medial Research Inc